Skip to main content
main-content

01.12.2014 | Original Article – Clinical Oncology | Ausgabe 12/2014

Journal of Cancer Research and Clinical Oncology 12/2014

Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 12/2014
Autoren:
Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00432-014-1758-4) contains supplementary material, which is available to authorized users.

Abstract

Purpose

The predictive value of excision repair cross-complementation group 1 (ERCC1) gene for survival and response to platinum-based chemotherapy in gastric cancer (GC) remains controversial. We performed a meta-analysis to clarify the precise estimation of the prognostic and predictive effect of ERCC1.

Methods

A systematic literature search was conducted using PubMed, ScienceDirect, Wiley and American Society of Clinical Oncology (ASCO) before March 2014. Studies analyzing survival data and/or chemotherapy response in GC by ERCC1 status were identified. The principal outcome measures were hazard ratios (HRs) for survival and relative risks (RRs) for chemotherapy response. Pooled HRs and RRs were calculated using fixed- or random-effects models according to the heterogeneity.

Results

Twenty-one studies involving 1,628 patients met our inclusion criteria. High ERCC1 expression was significantly associated with shorter overall survival (OS) and lower response to chemotherapy in advanced GC patients receiving palliative chemotherapy (HR 1.83; 95 % CI 1.45–2.31; P < 0.001; RR 0.49; 95 % CI 0.38–0.62; P < 0.001). There was no significant difference in survival between high and low ERCC1 expression in adjuvant setting (OS: HR 1.38; 95 % CI 0.77–2.45; P = 0.276; EFS 0.72; 95 % CI 0.38–1.33; P = 0.291). Some evidence of heterogeneity and possible publication bias were discovered in few meta-analyses.

Conclusions

High ERCC1 expression might be an adverse prognostic and a drug-resistance predictive factor for advanced GC patients. However, further studies with consistent ERCC1 assessment methodology are needed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (TIFF 1695 kb)
432_2014_1758_MOESM1_ESM.tif
Supplementary material 2 (TIFF 1450 kb)
432_2014_1758_MOESM2_ESM.tif
Supplementary material 3 (TIFF 1571 kb)
432_2014_1758_MOESM3_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 12/2014

Journal of Cancer Research and Clinical Oncology 12/2014 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise